Early Antiviral Therapy for Critically Ill HIV Infected Patients
Status:
Completed
Trial end date:
2016-06-30
Target enrollment:
Participant gender:
Summary
The aim of the study is to verify the effect of HAART in critically ill HIV infected
patients. The current practice is to begin antiviral therapy after ICU discharge, when the
condition of the patient is more stable. The investigators hypothesis is that the
investigators can improve outcome of these patients with earlier antiviral therapy in the
ICU. The investigators just have retrospective studies in this scenario. After admission to
ICU, patients are assigned to one of two arms: early HAART (within 5 days of ICU admission)
or conventional therapy (initiation of HAART after ICU discharge). The following data will be
collected: demographic variables, CD4 count, viral load, drug toxicity, opportunistic
infection, hemodialysis, mechanical ventilation and vasoactive drug. The patients will be
followed to determine ICU mortality, hospital mortality and 6-month mortality.